Page last updated: 2024-08-23

pirfenidone and tofacitinib

pirfenidone has been researched along with tofacitinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Bonella, F; Grunewald, J; Miedema, JR; Spagnolo, P	1
Fu, PK; Tseng, CW; Wang, KL; Yen, TH	1

Reviews

1 review(s) available for pirfenidone and tofacitinib

Article	Year
Looking into the future of sarcoidosis: what is next for treatment? Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:5 Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Biological Products; Cytokines; Dendritic Cells; Fibrosis; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammasomes; Macrophages; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Sarcoidosis; T-Lymphocytes	2020

Article

Year

Looking into the future of sarcoidosis: what is next for treatment?

Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:5

Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Biological Products; Cytokines; Dendritic Cells; Fibrosis; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammasomes; Macrophages; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Sarcoidosis; T-Lymphocytes

2020

Other Studies

1 other study(ies) available for pirfenidone and tofacitinib

Article	Year
Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina (Kaunas, Lithuania), 2021, Dec-13, Volume: 57, Issue:12 Topics: Autoantibodies; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Piperidines; Pyridones; Pyrimidines; Rituximab	2021

Article

Year

Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.

Medicina (Kaunas, Lithuania), 2021, Dec-13, Volume: 57, Issue:12

Topics: Autoantibodies; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Piperidines; Pyridones; Pyrimidines; Rituximab

2021